看之前记得先点个关注,欢迎投稿共创。药圈观察局,最新观察:本文为共创内容,作者:#药圈观察局2组云顶新耀宣布与陕西麦科奥特签署独家商业化许可协议,获得双靶点多肽新药MT1013在中国及亚太区(日本除外)的独家商业化授权。根据协议,云顶新耀将支付2亿元首付款,以及最高不超过10.4亿元的潜在监管及商业里程碑付款,交易总额达12.4亿元。目前,MT1013的中国III期临床研究正在进行中,而相关临床...
Source Link看之前记得先点个关注,欢迎投稿共创。药圈观察局,最新观察:本文为共创内容,作者:#药圈观察局2组云顶新耀宣布与陕西麦科奥特签署独家商业化许可协议,获得双靶点多肽新药MT1013在中国及亚太区(日本除外)的独家商业化授权。根据协议,云顶新耀将支付2亿元首付款,以及最高不超过10.4亿元的潜在监管及商业里程碑付款,交易总额达12.4亿元。目前,MT1013的中国III期临床研究正在进行中,而相关临床...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.